Evidence map›Paper›PMID 41142636›Full record

ArticleEngineering in life sciences2025

A Differential Depth Sequencing Method, SPRE-Seq, for Enhancing Targeted Region Coverage in Hybridization Capture-Based NGS.

Hui-Juan Chen, Bing Wang, Yi-Ran Zhang, Xue-Na Yao, Chun-Yan Yang, He-Nan Dong, Li-Li Cai, Dong-Jie Fan, Qi-Ming Zhou

Abstract read
In one paragraph

Article in Engineering in life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hui-Juan ChenBeijing CapitalBio MedLab Co., Ltd Beijing P.R. China.ORCID https://orcid.org/0000-0003-1126-2324
Bing WangBeijing Shuimu Jiheng Biotechnology Co., Ltd Beijing P.R. China.
Yi-Ran ZhangBeijing SeqTide Gene Technology Co., Ltd Beijing P.R. China.
Xue-Na YaoBeijing CapitalBio MedLab Co., Ltd Beijing P.R. China.
Chun-Yan YangBeijing SeqTide Gene Technology Co., Ltd Beijing P.R. China.
He-Nan DongBeijing Best Healthcare Medical Technology Co., Ltd Beijing P.R. China.
Li-Li CaiSchool of Software Beihang University Beijing P.R. China.
Dong-Jie FanNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease National Institute for Communicable Disease Control and Prevention, Chinese Center For Disease Control and Prevention Beijing P.R. China.
Qi-Ming ZhouSchool of Life Science and Technology Harbin Institute of Technology Harbin P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sequencing depth is a crucial parameter for variant calling accuracy and sensitivity. The trade-off between sequencing breadth and depth is a well-known limitation in capture-based targeted next-generation sequencing (NGS). Herein, we propose a differential depth sequencing method, SPRE-Seq, to acquire different sequencing depths for different targeted regions in an NGS panel. The SPRE-Seq performance was evaluated using a panel of reference standards and clinical samples based on our custom-designed homologous recombination deficiency (HRD) assay. By applying SPRE-Seq, the effective sequencing depths of the homologous recombination repair (HRR) and HRD regions of all seven HRD reference standards met the required thresholds with only half the sequencing data volume (reduced from 12 to 6 GB). The results for the HRR genes and HRD showed 100% consistency with the expected results. In clinical samples, the effective sequencing depth of the HRR regions was significantly higher, with a sequencing data volume of 6 GB using the SPRE-Seq approach compared with 6 GB using a regular capture approach. However, there was no significant difference between a data volume of 6 GB using SPRE-Seq and 12 GB using a regular capture method. The SPRE-Seq approach was feasible and reliable for determining the HRD status and HRR somatic variants in reference standards and clinical samples at a low sequencing volume. SPRE-Seq is a reliable, feasible, and cost-effective method that can acquire an adequate sequencing depth of an NGS panel at a low sequencing data volume.

Indexed as

hybridization capture‐based next‐generation sequencingoligonucleotide probessequencing depth

Identifiers

PMID41142636
PMCPMC12552348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.